ZTS Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 25.08% compared to Zoetis's net margin of 32.59%. Zoetis's return on equity of 49.71% beat Eli Lilly and's return on equity of 80.24%.

Zoetis has a consensus price target of $199.87, signalling upside risk potential of 33.75%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.63 which suggests that it could grow by 37.99%. Given that Eli Lilly and has higher upside potential than Zoetis, analysts believe Eli Lilly and is more attractive than Zoetis.

Zoetis has a beta of 0.925, which suggesting that the stock is 7.51% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.2%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Zoetis pays 31.62% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.3B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Zoetis's net income of $581M is lower than Eli Lilly and's net income of $4.4B. Notably, Zoetis's price-to-earnings ratio is 27.32x while Eli Lilly and's PE ratio is 62.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.34x versus 14.70x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 25.08% compared to Zoetis's net margin of 23.96%. Zoetis's return on equity of 49.71% beat Merck &'s return on equity of 40.25%.

Zoetis has a consensus price target of $199.87, signalling upside risk potential of 33.75%. On the other hand Merck & has an analysts' consensus of $110.89 which suggests that it could grow by 40.04%. Given that Merck & has higher upside potential than Zoetis, analysts believe Merck & is more attractive than Zoetis.

Zoetis has a beta of 0.925, which suggesting that the stock is 7.51% less volatile than S&P 500. In comparison Merck & has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.879%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.2%. Merck & offers a yield of 3.99% to investors and pays a quarterly dividend of $0.81 per share. Zoetis pays 31.62% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.3B, which are smaller than Merck & quarterly revenues of $15.6B. Zoetis's net income of $581M is lower than Merck &'s net income of $3.7B. Notably, Zoetis's price-to-earnings ratio is 27.32x while Merck &'s PE ratio is 11.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.34x versus 3.14x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 25.08% compared to Zoetis's net margin of 2.31%. Zoetis's return on equity of 49.71% beat Pfizer's return on equity of 8.91%.

Zoetis has a consensus price target of $199.87, signalling upside risk potential of 33.75%. On the other hand Pfizer has an analysts' consensus of $30.54 which suggests that it could grow by 39.41%. Given that Pfizer has higher upside potential than Zoetis, analysts believe Pfizer is more attractive than Zoetis.

Zoetis has a beta of 0.925, which suggesting that the stock is 7.51% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.2%. Pfizer offers a yield of 7.71% to investors and pays a quarterly dividend of $0.43 per share. Zoetis pays 31.62% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Zoetis quarterly revenues are $2.3B, which are smaller than Pfizer quarterly revenues of $17.8B. Zoetis's net income of $581M is higher than Pfizer's net income of $410M. Notably, Zoetis's price-to-earnings ratio is 27.32x while Pfizer's PE ratio is 15.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.34x versus 1.96x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 25.08% compared to Zoetis's net margin of 8.8%. Zoetis's return on equity of 49.71% beat Supernus Pharmaceuticals's return on equity of 7.61%.

Zoetis has a consensus price target of $199.87, signalling upside risk potential of 33.75%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 22.51%. Given that Zoetis has higher upside potential than Supernus Pharmaceuticals, analysts believe Zoetis is more attractive than Supernus Pharmaceuticals.

Zoetis has a beta of 0.925, which suggesting that the stock is 7.51% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.882%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.2%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 31.62% of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.3B, which are larger than Supernus Pharmaceuticals quarterly revenues of $174.2M. Zoetis's net income of $581M is higher than Supernus Pharmaceuticals's net income of $15.3M. Notably, Zoetis's price-to-earnings ratio is 27.32x while Supernus Pharmaceuticals's PE ratio is 23.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.34x versus 2.68x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.